Eli Lilly Announces Q4 Results

Eli Lilly announced that its net income fell 27 percent in the last quarter of 2011.

U.S. pharmaceutical company Eli Lilly has announced its financial results for the fourth quarter of 2011.

The company's U.S. revenue was down 4% to $3.3 billion due to the loss of patent exclusivity for Zyprexa and Gemzar. Revenue outside the U.S. remained flat at $2.8 billion due to increased volume and the positive impact of foreign exchange rates, offset by lower prices.

For the year revenue in the U.S. was $13.0 billion (+1%). Revenue outside the U.S. increased 11% to $11.3 billion due to increased demand and the positive impact of foreign exchange rates, partially offset by lower prices.

Zyprex